Catherine H Marshall1, Alexandra O Sokolova2, Andrea L McNatty3, Heather H Cheng2, Mario A Eisenberger1, Alan H Bryce3, Michael T Schweizer2, Emmanuel S Antonarakis4. 1. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA. 2. Division of Medical Oncology, University of WashingtonUSA; Division of Clinical Research, Fred Hutch Cancer Research Center Seattle, Washington, USA. 3. Department of Oncology, Mayo Clinic, Scottsdale, AZ, USA. 4. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address: eantona1@jhmi.edu.
Abstract
BACKGROUND: Poly ADP-ribose polymerase (PARP) inhibitors, such as olaparib, are being explored as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) in men harboring mutations in homologous recombination DNA-repair genes. Whether responses to PARP inhibitors differ according to the affected gene is currently unknown. OBJECTIVE: To determine whether responses to PARP inhibitors differ between men with BRCA1/2 and those with ATM mutations. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter retrospective review of 23 consecutive men with mCRPC and pathogenic germline and/or somatic BRCA1/2 or ATM mutations treated with olaparib at three academic sites in the USA. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The proportion of patients achieving a ≥50% decline in prostate-specific antigen (PSA50 response) was compared using Fisher's exact test. Clinical and radiographic progression-free survival (PFS) and overall survival were estimated using Kaplan-Meier analyses and compared using the log-rank test. RESULTS AND LIMITATIONS: The study included two men with BRCA1 mutations, 15 with BRCA2 mutations, and six with ATM mutations. PSA50 responses to olaparib were achieved in 76% (13/17) of men with BRCA1/2 versus 0% (0/6) of men with ATM mutations (Fisher's exact test; p=0.002). Patients with BRCA1/2 mutations had median PFS of 12.3mo versus 2.4mo for those with ATM mutations (hazard ratio 0.17, 95% confidence interval 0.05-0.57; p=0.004). Limitations include the retrospective design and relatively small sample size. CONCLUSIONS: Men with mCRPC harboring ATM mutations experienced inferior outcomes to PARP inhibitor therapy compared to those harboring BRCA1/2 mutations. Alternative therapies should be explored for patients with ATM mutations. PATIENT SUMMARY: Mutations in BRCA1/2 and ATM genes are common in metastatic prostate cancer. In this study we compared outcomes for men with BRCA1/2 mutations to those for men with ATM mutations being treated with olaparib. We found that men with ATM mutations do not respond as well as men with BRCA1/2 mutations.
BACKGROUND:Poly ADP-ribose polymerase (PARP) inhibitors, such as olaparib, are being explored as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) in men harboring mutations in homologous recombination DNA-repair genes. Whether responses to PARP inhibitors differ according to the affected gene is currently unknown. OBJECTIVE: To determine whether responses to PARP inhibitors differ between men with BRCA1/2 and those with ATM mutations. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter retrospective review of 23 consecutive men with mCRPC and pathogenic germline and/or somatic BRCA1/2 or ATM mutations treated with olaparib at three academic sites in the USA. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The proportion of patients achieving a ≥50% decline in prostate-specific antigen (PSA50 response) was compared using Fisher's exact test. Clinical and radiographic progression-free survival (PFS) and overall survival were estimated using Kaplan-Meier analyses and compared using the log-rank test. RESULTS AND LIMITATIONS: The study included two men with BRCA1 mutations, 15 with BRCA2 mutations, and six with ATM mutations. PSA50 responses to olaparib were achieved in 76% (13/17) of men with BRCA1/2 versus 0% (0/6) of men with ATM mutations (Fisher's exact test; p=0.002). Patients with BRCA1/2 mutations had median PFS of 12.3mo versus 2.4mo for those with ATM mutations (hazard ratio 0.17, 95% confidence interval 0.05-0.57; p=0.004). Limitations include the retrospective design and relatively small sample size. CONCLUSIONS:Men with mCRPC harboring ATM mutations experienced inferior outcomes to PARP inhibitor therapy compared to those harboring BRCA1/2 mutations. Alternative therapies should be explored for patients with ATM mutations. PATIENT SUMMARY: Mutations in BRCA1/2 and ATM genes are common in metastatic prostate cancer. In this study we compared outcomes for men with BRCA1/2 mutations to those for men with ATM mutations being treated with olaparib. We found that men with ATM mutations do not respond as well as men with BRCA1/2 mutations.
Authors: Bella Kaufman; Ronnie Shapira-Frommer; Rita K Schmutzler; M William Audeh; Michael Friedlander; Judith Balmaña; Gillian Mitchell; Georgeta Fried; Salomon M Stemmer; Ayala Hubert; Ora Rosengarten; Mariana Steiner; Niklas Loman; Karin Bowen; Anitra Fielding; Susan M Domchek Journal: J Clin Oncol Date: 2014-11-03 Impact factor: 44.544
Authors: Matti Annala; Gillian Vandekerkhove; Daniel Khalaf; Sinja Taavitsainen; Kevin Beja; Evan W Warner; Katherine Sunderland; Christian Kollmannsberger; Bernhard J Eigl; Daygen Finch; Conrad D Oja; Joanna Vergidis; Muhammad Zulfiqar; Arun A Azad; Matti Nykter; Martin E Gleave; Alexander W Wyatt; Kim N Chi Journal: Cancer Discov Date: 2018-01-24 Impact factor: 39.397
Authors: Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Chao Liang; Hao Wang; Yan Chen; John L Silberstein; Danilo Piana; Zhao Lai; Yidong Chen; William B Isaacs; Jun Luo Journal: Eur Urol Date: 2018-02-10 Impact factor: 20.096
Authors: Brennan Decker; Danielle M Karyadi; Brian W Davis; Eric Karlins; Lori S Tillmans; Janet L Stanford; Stephen N Thibodeau; Elaine A Ostrander Journal: Am J Hum Genet Date: 2016-04-14 Impact factor: 11.025
Authors: Matti Annala; Werner J Struss; Evan W Warner; Kevin Beja; Gillian Vandekerkhove; Amanda Wong; Daniel Khalaf; Irma-Liisa Seppälä; Alan So; Gregory Lo; Rahul Aggarwal; Eric J Small; Matti Nykter; Martin E Gleave; Kim N Chi; Alexander W Wyatt Journal: Eur Urol Date: 2017-03-01 Impact factor: 20.096
Authors: Yi-Mi Wu; Marcin Cieślik; Robert J Lonigro; Pankaj Vats; Melissa A Reimers; Xuhong Cao; Yu Ning; Lisha Wang; Lakshmi P Kunju; Navonil de Sarkar; Elisabeth I Heath; Jonathan Chou; Felix Y Feng; Peter S Nelson; Johann S de Bono; Weiping Zou; Bruce Montgomery; Ajjai Alva; Dan R Robinson; Arul M Chinnaiyan Journal: Cell Date: 2018-06-14 Impact factor: 41.582
Authors: Joshua Armenia; Stephanie A M Wankowicz; David Liu; Jianjiong Gao; Ritika Kundra; Ed Reznik; Walid K Chatila; Debyani Chakravarty; G Celine Han; Ilsa Coleman; Bruce Montgomery; Colin Pritchard; Colm Morrissey; Christopher E Barbieri; Himisha Beltran; Andrea Sboner; Zafeiris Zafeiriou; Susana Miranda; Craig M Bielski; Alexander V Penson; Charlotte Tolonen; Franklin W Huang; Dan Robinson; Yi Mi Wu; Robert Lonigro; Levi A Garraway; Francesca Demichelis; Philip W Kantoff; Mary-Ellen Taplin; Wassim Abida; Barry S Taylor; Howard I Scher; Peter S Nelson; Johann S de Bono; Mark A Rubin; Charles L Sawyers; Arul M Chinnaiyan; Nikolaus Schultz; Eliezer M Van Allen Journal: Nat Genet Date: 2018-04-02 Impact factor: 38.330
Authors: Andrea K Miyahira; Adam Sharp; Leigh Ellis; Jennifer Jones; Salma Kaochar; H Benjamin Larman; David A Quigley; Huihui Ye; Jonathan W Simons; Kenneth J Pienta; Howard R Soule Journal: Prostate Date: 2019-12-11 Impact factor: 4.104
Authors: Shahrzad Rafiei; Kenyon Fitzpatrick; David Liu; Mu-Yan Cai; Haitham A Elmarakeby; Jihye Park; Cora Ricker; Bose S Kochupurakkal; Atish D Choudhury; William C Hahn; Steven P Balk; Justin H Hwang; Eliezer M Van Allen; Kent W Mouw Journal: Cancer Res Date: 2020-03-03 Impact factor: 12.701
Authors: Bin Gui; Fu Gui; Tomoaki Takai; Chao Feng; Xiao Bai; Ladan Fazli; Xuesen Dong; Shuai Liu; Xiaofeng Zhang; Wei Zhang; Adam S Kibel; Li Jia Journal: Proc Natl Acad Sci U S A Date: 2019-07-02 Impact factor: 11.205
Authors: Alexandra O Sokolova; Catherine H Marshall; Rebeca Lozano; Roman Gulati; Elisa M Ledet; Navonil De Sarkar; Petros Grivas; Celestia S Higano; Bruce Montgomery; Peter S Nelson; David Olmos; Vadim Sokolov; Michael T Schweizer; Todd A Yezefski; Evan Y Yu; Channing J Paller; Oliver Sartor; Elena Castro; Emmanuel S Antonarakis; Heather H Cheng Journal: Prostate Date: 2021-09-13 Impact factor: 4.104
Authors: Burcu F Darst; Tokhir Dadaev; Ed Saunders; Xin Sheng; Peggy Wan; Loreall Pooler; Lucy Y Xia; Stephen Chanock; Sonja I Berndt; Susan M Gapstur; Victoria Stevens; Demetrius Albanes; Stephanie J Weinstein; Vincent Gnanapragasam; Graham G Giles; Tu Nguyen-Dumont; Roger L Milne; Mark Pomerantz; Julie A Schmidt; Lorelei Mucci; William J Catalona; Kurt N Hetrick; Kimberly F Doheny; Robert J MacInnis; Melissa C Southey; Rosalind A Eeles; Fredrik Wiklund; Zsofia Kote-Jarai; David V Conti; Christopher A Haiman Journal: J Natl Cancer Inst Date: 2021-05-04 Impact factor: 13.506
Authors: Emmanuel S Antonarakis; Tamara L Lotan; Harsimar Kaur; Daniela C Salles; Sanjana Murali; Jessica L Hicks; Minh Nguyen; Colin C Pritchard; Angelo M De Marzo; Jerry S Lanchbury; Bruce J Trock; William B Isaacs; Kirsten M Timms Journal: Clin Cancer Res Date: 2020-07-21 Impact factor: 12.531
Authors: Veda N Giri; Karen E Knudsen; William K Kelly; Heather H Cheng; Kathleen A Cooney; Michael S Cookson; William Dahut; Scott Weissman; Howard R Soule; Daniel P Petrylak; Adam P Dicker; Saud H AlDubayan; Amanda E Toland; Colin C Pritchard; Curtis A Pettaway; Mary B Daly; James L Mohler; J Kellogg Parsons; Peter R Carroll; Robert Pilarski; Amie Blanco; Ashley Woodson; Alanna Rahm; Mary-Ellen Taplin; Thomas J Polascik; Brian T Helfand; Colette Hyatt; Alicia K Morgans; Felix Feng; Michael Mullane; Jacqueline Powers; Raoul Concepcion; Daniel W Lin; Richard Wender; James Ryan Mark; Anthony Costello; Arthur L Burnett; Oliver Sartor; William B Isaacs; Jianfeng Xu; Jeffrey Weitzel; Gerald L Andriole; Himisha Beltran; Alberto Briganti; Lindsey Byrne; Anne Calvaresi; Thenappan Chandrasekar; David Y T Chen; Robert B Den; Albert Dobi; E David Crawford; James Eastham; Scott Eggener; Matthew L Freedman; Marc Garnick; Patrick T Gomella; Nathan Handley; Mark D Hurwitz; Joseph Izes; R Jeffrey Karnes; Costas Lallas; Lucia Languino; Stacy Loeb; Ana Maria Lopez; Kevin R Loughlin; Grace Lu-Yao; S Bruce Malkowicz; Mark Mann; Patrick Mille; Martin M Miner; Todd Morgan; Jose Moreno; Lorelei Mucci; Ronald E Myers; Sarah M Nielsen; Brock O'Neil; Wayne Pinover; Peter Pinto; Wendy Poage; Ganesh V Raj; Timothy R Rebbeck; Charles Ryan; Howard Sandler; Matthew Schiewer; E Michael D Scott; Brittany Szymaniak; William Tester; Edouard J Trabulsi; Neha Vapiwala; Evan Y Yu; Charnita Zeigler-Johnson; Leonard G Gomella Journal: J Clin Oncol Date: 2020-06-09 Impact factor: 44.544